摘要
目的评价母牛分枝杆菌菌苗（微卡）在治疗卡介苗反应性淋巴结炎的临床效果，为治疗卡介苗反应性淋巴结炎提供参考依据。方法搜集2012年1月至2015年7月上海市公共卫生临床中心的住院卡介苗反应性淋巴结炎患儿74例。根据患儿家属的治疗意愿，25例患儿口服异烟肼、利福平抗结核药物治疗（抗结核治疗组），44例患儿接受微卡治疗（微卡组），5例先天性免疫缺陷病患儿口服异烟肼、利福平、乙胺丁醇抗结核＋微卡治疗。比较抗结核治疗组和微卡组患儿的治疗效果和不良反应。应用SPSS21．0软件处理数据，组间比较采用；X2检验，以P〈0．05为差异有统计学意义。结果抗结核治疗组100．0％（25／25）患儿淋巴结肿大均逐渐消退，微卡组95．5％（42／44）淋巴结肿大逐渐消退，两组有效率比较差异无统计学意义（X2=1．170，P〉0．05）。抗结核药物治疗组16．0％（4／25）的出现肝功能损伤，微卡组无患儿出现肝功能损伤，两组肝损伤发生率比较差异有统计学意义（X2=7．473，P〈0．05）。结论采用微卡治疗卡介苗反应性淋巴结炎具有较好的效果，且可减少患儿不良反应的发生。
Objective To evaluate the clinical efficacy of antituberculosis drugs and cow mycobacteria vaccine （M. vaccine） in the treatment of BCG reactive lymph node phlogistic （BCG-isis）, given reference basis to treat this kind of disease. Methods Seventy four inpatients with BCG reactive lymph node phlogistic were enrolled in the Shanghai Public Health Clinical Center from Jan. 2012 to Jul. 2012. According to the treatment intention from family members of children＇ s, 25 cases taken with isoniazid and rifampicin （anti-tb treatment group）, 44 cases treated with M. vaccine （M. vaccine group）, and 5 cases with congenital immunodeficiency disease treated with isoniazid, rifampin, ethambutol rib plus M. vaccine. The efficacy and adverse reactions were compared between an- ti-tuberculosis treatment group and the M. vaccine treatment group. Data analysis were applied with SPSS 21.0 software, P〈0. 05 as significant difference with statistics. Results All patients were observed with enlarged lymph nodes fading （25/25,100%） in antituberculosis treatment group, 42 （42/44,95.5 %） patients were observed the same reliving in M. vaccine group. There was no statistical difference between the two groups （Z2= 1. 170, P〉 0. 05）. However, there were 4 （4/25, 16.0%） patients with liver damage in antituberculosis treatment group and no one with liver injury in M. vaccine group. The incidence of liver damage was difference significantly between the two groups （Z2= 7. 473, P〈0.05）. Conclusion The treatment with M. vaccine only for BCG reactive lymph node phlogistic has good efficacy, and without adverse reactions of live injury in children.
出处
《中国防痨杂志》
CAS
2016年第3期189-192,共4页
Chinese Journal of Antituberculosis
基金
上海市公共卫生临床中心课题（2015-10）
关键词
抗结核药
分枝杆菌牛
分枝杆菌
淋巴结核
治疗结果
Antitubercular agents
Myeobacterium bovis
Mycobacterium scrofulaceum
Treatment outcome
